BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17033232)

  • 1. [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
    Shiiki S; Sonoo H; Seki M; Nomura T; Hironou M; Ookubo S; Udagawa K; Yamamoto Y; Nakashima K; Ikeda M; Tanaka K; Kurebayashi J
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1431-5. PubMed ID: 17033232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
    Wang T; Jiang ZF; Song ST; Zhang SH; Shen G; Yu JX
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):379-81. PubMed ID: 15312353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [More effective positioning of capecitabine for advanced and metastatic breast cancer].
    Tsuyuki S; Kawaguchisakita N; Tsubota Y; Ukikusa M; Kohno Y
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):649-53. PubMed ID: 20414020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
    Amari M; Ishida T; Takeda M; Ohuchi N
    Jpn J Clin Oncol; 2010 Mar; 40(3):188-93. PubMed ID: 19887522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
    Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
    Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
    Hess D; Koberle D; Thurlimann B; Pagani O; Schonenberger A; Mattmann S; Rochlitz C; Rauch D; Schuller JC; Ballabeni P; Ribi K;
    Oncology; 2007; 73(3-4):228-37. PubMed ID: 18424887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
    Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
    Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
    Yap YS; Kendall A; Walsh G; Banerji U; Johnston SR; Smith IE; O'Brien M
    Breast; 2007 Aug; 16(4):420-4. PubMed ID: 17379519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
    Saeki T; Kimura T; Toi M; Taguchi T
    Breast Cancer; 2006; 13(1):49-57. PubMed ID: 16518062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
    Akahane T; Chiba T; Yano H; Hashimoto Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):435-8. PubMed ID: 17353638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.
    Sezgin C; Kurt E; Evrensel T; Ozdemir N; Manavoglu O; Goker E
    South Med J; 2007 Jan; 100(1):27-32. PubMed ID: 17269522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.